Previous close | 323.75 |
Open | 325.20 |
Bid | 323.20 x N/A |
Ask | 323.35 x N/A |
Day's range | 322.20 - 326.35 |
52-week range | 306.50 - 357.65 |
Volume | |
Avg. volume | 19,779,244 |
Market cap | 29.846B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 24.86 |
EPS (TTM) | 0.13 |
Earnings date | 02 Nov 2023 |
Forward dividend & yield | 0.04 (1.11%) |
Ex-dividend date | 24 Aug 2023 |
1y target est | 359.75 |
Year 2 Health Inclusivity Index Scores Under phase two of the Health Inclusivity Index, Australia achieves the highest score, followed by Sweden, UK, USA, France, Israel, Canada, South Korea, Germany, Switzerland and Thailand Phase two of Economist Impact’s Health Inclusivity Index, supported by Haleon, measures experience of health inclusion across 42,000 people in 40 countriesHealth inclusivity scores fall worldwide with addition of lived experience data, exposing glaring policy-practice gap i
Year 2 Health Inclusivity Scores Under phase two of the Health Inclusivity Index, Australia achieves the highest score, followed by Sweden, UK, USA, France, Israel, Canada, South Korea, Germany, Switzerland and Thailand More than three in five (63%) people in the UK experience barriers to health inclusionPeople in UK, Canada and France face the longest waiting times to see a GPHealth inclusivity scores fall worldwide with addition of lived experience data in Economist Impact’s Health Inclusivity
Economist Impact, an arm of The Economist Group that works with organisations globally to further their missions, today launched phase two of the Health Inclusivity Index, supported by Haleon (LSE / NYSE: HLN), a global leader in consumer health. This phase's results show health inclusivity falling worldwide, and notably Britain falling from its top spot in phase one.